Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Medical In-Licenses China Rights to VAXIMM's Immunotherapies

publication date: Sep 20, 2018

China Medical System in-licensed China/Asian rights (excluding Japan) to a portfolio of oral cancer immunotherapy candidates developed by VAXIMM, a Swiss/German biotech. In return for the rights, CMS will participate in VAXIMM's Series B round, plus make milestone payments and pay royalties. Specific details were not disclosed. VAXIMM's candidates are based on an orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells. More details....

Stock Symbol: (HK: 0867)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.